INmune Bio (INMB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$1.3M

Net income growth (year over year)

+94.80%

Net margin

—

Return on equity

−74.82%

EPS (trailing twelve months)

−$0.62

Book value per share

$0.74

P/E (trailing twelve months)

—

Price to book

2.28

Debt to assets

24.15%

Payout ratio

—

Dividend yield

—

Company profile

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

• How do I buy stock in INmune Bio (INMB)?

  INMB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.